Drug Trial Radar · NCT02118792
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Mar 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
764
Actual
Start
Mar 2014
Primary completion
Apr 2015
Study completion Apr 2015
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
Conditions
- Dermatitis, Atopic
Interventions
AN2728 Topical Ointment, 2%Drug
Matching vehicle controlDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29Time frame: Day 29
- Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)Time frame: AEs: Baseline (Day 1) up to Day 29, SAEs: Baseline (Day 1) up to Day 36
- Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings at Day 8Time frame: Baseline, Day 8
- Number of Participants With Clinically Significant Change From Baseline in Vital Signs at Day 36Time frame: Baseline (Day 1), Day 36
- Number of Participants With Clinically Significant Laboratory ValuesTime frame: Baseline up to Day 36
- Percentage of Participants With Local Tolerability Symptoms at BaselineTime frame: Baseline (Day 1)
- Percentage of Participants With Local Tolerability Symptoms at Day 8Time frame: Day 8
- Percentage of Participants With Local Tolerability Symptoms at Day 15Time frame: Day 15
- Percentage of Participants With Local Tolerability Symptoms at Day 22Time frame: Day 22
- Percentage of Participants With Local Tolerability Symptoms at Day 29Time frame: Day 29
- Percentage of Participants With Local Tolerability Symptoms at Day 36Time frame: Day 36
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anacor Investigational Site
Henrico, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.